Skip to main content
MyDeficiencies

Insulin aspart

Fast-Acting Insulin Analogue

Also sold as NovoLog, NovoRapid, Fiasp.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Insulin aspart has no classical drug-nutrient depletion mechanism in the pharmacokinetic sense. It is a 51-amino-acid peptide given by injection, not metabolized by CYP450 enzymes, not orally absorbed (so chelation, gastric-pH, and bile-acid mechanisms do not apply), and not excreted unchanged by the kidney in a way that wastes nutrients through tubular loss. What it does have is direct, well-documented hormone pharmacology: insulin is the body's principal anabolic hormone, and its intended action of driving glucose into cells also drives potassium, and to a lesser extent phosphate, into cells. The insulin aspart label itself states that this analog, like other insulins, can shift potassium from outside to inside cells and cause hypokalemia, and separately can cause sodium retention and edema when glycemic control improves. Both are on-label, drug-specific findings, but they are physiologic shifts and retention effects, not dietary deficiencies, and are graded and framed accordingly below.

Insulins and analogues, fast-acting · ATC A10AB05 · also sold as NovoLog and Fiasp and NovoRapid and Trurapi and Merilog · reviewed 2026-09-20. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Insulin aspart in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
severe: two or more independent Tier A sources, this drug in the studied cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
moderate: at least one Tier A source with this drug in the cohort showing a real deficit or disturbance, but bounded by exposure window, subgroup, frequency, or a functional (not just circulating) measure.
Yellow — Low
low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective findings.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: evidence gap: no Tier B/C evidence exists to support even a yellow grade, and no circulating claim exists to rebut as white. A disclosed gap in the literature or in what could be accessed during this review, never reworded as reassurance.

What the research found

Potassium

Orange — Moderate

See study details

Insulin aspart, like all insulins, drives a dose-related shift of potassium into cells and can cause clinically significant hypokalemia; risk is concentrated in IV/high-dose use, DKA correction, renal impairment, and concurrent potassium-lowering drugs, not routine mealtime subcutaneous dosing.

Full detail and limits

What the grade means here: moderate: at least one Tier A source with this drug in the cohort showing a real deficit or disturbance, but bounded by exposure window, subgroup, frequency, or a functional (not just circulating) measure. Orange

Limits on what this shows

  • Key negative/null: No aspart-specific trial quantifying magnitude in routine subcutaneous mealtime dosing was located; effect is understood to be dose- and route-dependent (larger with IV/high-dose use than typical subcutaneous dosing).
  • At-risk subgroups: Renal impairment, concurrent potassium-lowering drugs (diuretics, beta-agonists), DKA correction, refeeding.

Regulatory status

On-label warning in the NovoLog (insulin aspart) U.S. prescribing information, Warnings and Precautions section.

Population evidence

Regulatory label statement (mechanism-based warning); consistent with class-level clinical literature on insulin-and-glucose treatment of hyperkalemia and DKA management, which documents the same shift with other insulin formulations.

Mechanism

Named: insulin binding to its receptor stimulates Na+/K+-ATPase activity, driving potassium into cells independent of any change in total body potassium.

Counter-evidence held on record

No source contradicts the existence of the shift; the disagreement in the literature is about magnitude, which is small and self-limited at typical subcutaneous replacement doses and larger during IV correction of hyperglycemia/DKA. This is a redistribution of existing body potassium, not a nutritional deficiency. Do not present this entry as grounds for routine potassium supplementation; serum potassium should be monitored and managed clinically, especially with renal impairment, DKA correction, or concurrent potassium-lowering drugs.

Sodium

Orange — Moderate

See study details

Insulin aspart, like other insulins, may cause sodium retention and edema, particularly when a patient's previously poor glycemic control is improved; this is a retention/excess-risk finding, not a sodium deficiency, and supplementation is never the implication.

Full detail and limits

What the grade means here: moderate: at least one Tier A source with this drug in the cohort showing a real deficit or disturbance, but bounded by exposure window, subgroup, frequency, or a functional (not just circulating) measure. Orange

Limits on what this shows

  • Key negative/null: Label frames this as occurring "particularly" in the setting of improving from poor control, i.e. a bounded exposure window rather than a universal chronic effect of every dose.
  • At-risk subgroups: Heart failure history, concurrent thiazolidinedione use, rapid intensification of glycemic control.

Regulatory status

On-label (NovoLog prescribing information, Adverse Reactions/Warnings and Precautions).

Population evidence

Regulatory label statement; label separately warns that thiazolidinediones combined with insulin increase dose-related fluid retention and heart-failure risk.

Mechanism

Named: insulin has a direct renal tubular antinatriuretic action (enhanced distal nephron sodium reabsorption); the label also attributes part of the effect to correction of previously poor metabolic control.

Counter-evidence held on record

None identified contradicting the retention effect; magnitude and persistence beyond the initial improvement window were not quantified in the label excerpt reviewed. Excess/retention direction: this entry must never imply sodium or fluid intake should increase. Sodium restriction and clinical monitoring for edema or heart failure symptoms, not supplementation, are the relevant considerations.

Phosphate

Yellow — Low

See study details

Insulin's stimulation of cellular glucose uptake also drives phosphate into cells, a recognized mechanism of hypophosphatemia during insulin treatment of hyperglycemia/DKA; no primary evidence specific to insulin aspart itself was found.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective findings. Yellow

Limits on what this shows

  • Key negative/null: A direct PubMed search for "insulin aspart" combined with "phosphate"/"hypophosphatemia" returned zero results.
  • At-risk subgroups: DKA correction, refeeding syndrome, malnourished patients starting insulin.

Regulatory status

Not addressed in the insulin aspart label reviewed.

Population evidence

A narrative review of hypophosphatemia (Imel & Econs, PMC3319220) describes the DKA-insulin mechanism without drug-level stratification (Tier C). A published case report of hypophosphatemia during insulin therapy for DKA exists (Yoshida et al., J Diabetes Investig, 2021), but the specific insulin formulation used in that case could not be confirmed during this review, so it is treated as class-level rather than aspart-specific.

Mechanism

Named: insulin-stimulated cellular glucose uptake is accompanied by phosphate co-transport into cells via sodium-phosphate cotransporters, lowering serum phosphate.

Counter-evidence held on record

No insulin aspart-specific trial identified in either direction; the mechanism is well characterized for insulin as a class (regular human insulin, IV protocols) rather than demonstrated for this analog specifically. Mechanistically plausible and pharmacologically well characterized for insulin as a class, but not verified for insulin aspart specifically. Do not present as an established aspart-specific finding, and make no phosphate dosing recommendation from this entry.

Magnesium

Not graded — disclosed evidence gap

See study details

No consistent drug-specific evidence was found that insulin aspart alters magnesium status.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: A PubMed search combining "insulin aspart" and "magnesium" returned no dedicated study. The only proximate finding was an incidental note, in an unrelated 2017 PubMed-indexed case report concerning muscle cramps, that magnesium was unchanged after an insulin injection while potassium dropped; this is recorded as a null finding (counter-evidence), though full bibliographic detail for that case report could not be confirmed because of an access rate-limit encountered during this review. Broader diabetes-hypomagnesemia literature is attributed in the sources reviewed to renal glucosuria and disease severity rather than to insulin's direct pharmacologic action, and is confounded by indication. A separate, reverse-direction claim was found ("lack of magnesium and calcium may cause poor response to insulin") describing magnesium affecting the drug, not the drug depleting magnesium; per the interaction-direction rule this is not a depletion claim against insulin and is not graded as one here. No "insulin depletes magnesium" consumer claim was found. Both conditions for ungraded are met.

Tooling note

A follow-up Crossref query intended to confirm the 2017 case report's full citation was blocked by proxy rate-limiting and not retried further in this session; a future revision should complete that citation check.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden

Yellow — Low

See study details

In animal models, recurrent insulin-induced hypoglycemia worsens neuronal mitochondrial dysfunction; this is a consequence of the hypoglycemic adverse event of imperfect dosing, not a separate toxic action of insulin aspart itself.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective findings. Yellow

Limits on what this shows

  • Key negative/null: The same insulin-receptor pathway, at physiologic non-hypoglycemic exposure, stimulates mitochondrial protein synthesis and oxidative phosphorylation in human muscle (see ATP production entry below; overlap disclosed in the overlap map).
  • At-risk subgroups: Recurrent or severe hypoglycemia, tight glycemic targets without adequate monitoring, hypoglycemia unawareness.

Regulatory status

Not addressed directly in the label; hypoglycemia itself is the label's primary warned adverse effect.

Population evidence

Animal studies (Tier B) in insulin-treated diabetic rats, e.g. a 2019 study on sodium dichloroacetate and mitochondrial dysfunction/neuronal death following hypoglycemia-induced injury, and a 2019 study on recurrent hypoglycemia worsening brain mitochondrial dysfunction in diabetic rat models. Insulin used in these models is not confirmed as insulin aspart specifically (class-level).

Mechanism

Named: hypoglycemia-induced upregulation of pyruvate dehydrogenase kinase suppresses ATP formation, and neuronal mitochondrial permeability changes with calcium overload occur during and after the hypoglycemic episode.

Counter-evidence held on record

Physiologic (non-hypoglycemic) insulin exposure is mitochondrially supportive in human muscle studies, directly opposing a blanket "insulin harms mitochondria" reading. This entry reflects a burden created by the drug's known, dose-related adverse effect (hypoglycemia), not a direct toxic mechanism of insulin aspart used as intended. Per the outcome-vs-nutrient distinction, this should never be read as evidence that correctly dosed insulin aspart damages mitochondria.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress

Yellow — Low

See study details

Chronic supraphysiologic insulin exposure increased oxidative-stress markers and induced insulin resistance in an adipocyte cell model; this conflicts with the broader, better-established point that improving glycemic control (insulin's intended effect) tends to lower hyperglycemia-driven oxidative stress.

Full detail and limits

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective findings. Yellow

Limits on what this shows

  • Key negative/null: Hyperglycemia itself is a well-established driver of oxidative stress; therapeutic glycemic control, the intended effect of insulin aspart, is generally associated with lower glucose-driven oxidative stress in clinical populations, running opposite to the in vitro finding.
  • At-risk subgroups: States of chronic hyperinsulinemia/insulin resistance rather than typical basal-bolus insulin aspart dosing in type 1 diabetes.

Regulatory status

Not addressed in the label.

Population evidence

In vitro study (Tier B): chronic insulin treatment causing insulin resistance in 3T3-L1 adipocytes through oxidative stress (Free Radical Research, 2008). Cell-model only, generic/unspecified insulin, not insulin aspart-specific and not a human study.

Mechanism

Named for the in vitro finding: sustained supraphysiologic insulin signaling promotes reactive oxygen species generation in adipocytes, contributing to cellular insulin resistance.

Counter-evidence held on record

Direction-dependent and conflicting: glycemic correction (insulin's therapeutic effect) generally reduces oxidative stress in vivo, while sustained supraphysiologic exposure in vitro increases it. Do not present as an established adverse effect of therapeutic insulin aspart dosing; the supporting evidence is a cell-model finding under supraphysiologic, chronic exposure conditions, not clinical dosing.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Copper

Yellow — Low

See study details

In streptozotocin-diabetic rats, insulin treatment normalized hepatic and renal copper (and zinc) handling that had been disturbed by uncontrolled diabetes; direction is protective/normalizing, not depleting.

Full detail, limits and 2 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective findings. Yellow

Limits on what this shows

  • Key negative/null: No study identified showing insulin itself lowering copper status in a non-diabetic or well-controlled context.
  • At-risk subgroups: None identified as an insulin-caused copper-deficiency risk.

Regulatory status

Not addressed in the label.

Population evidence

Animal study (Tier B): Failla & Kiser, "Hepatic and renal metabolism of copper and zinc in the diabetic rat," Am J Physiol Endocrinol Metab, 1983 (PMID 6824071); a related PubMed-listed 1985 report by Failla & Gardell (PMID 3901016) describes similar normalization of tissue zinc, copper, and manganese with daily insulin injections in diabetic rats.

Mechanism

Named: uncontrolled diabetes itself disturbs trace-mineral tissue distribution; insulin, by correcting the underlying metabolic derangement, restores more normal handling. No direct insulin-copper cofactor antagonism mechanism was found.

Counter-evidence held on record

None found opposing the normalizing direction; all located evidence points the same way (correction, not depletion). Reverse-direction/protective finding. This must never be used to suggest insulin aspart depletes copper, and no copper supplementation is indicated by this entry.

  • Failla ML, Kiser RA. Hepatic and renal metabolism of copper and zinc in the diabetic rat. Am J Physiol Endocrinol Metab. 1983;244(2):E115. DOI 10.1152/ajpendo.1983.244.2.e115. PMID 6824071. — Animal study (STZ-diabetic rats), insulin treatment effect on copper status in liver, kidney, intestine.
  • Failla ML, Gardell CY. Effect of insulin treatment on tissue zinc, copper, and manganese in the diabetic rat, 1985. PMID 3901016 (identified via PubMed search listing). — Animal study, BB Wistar diabetic rats; daily insulin injections normalized tissue trace-mineral changes.Full text not opened; details drawn from PubMed search-results listing view.

Iron

Yellow — Low

See study details

In streptozotocin-diabetic rat models, insulin treatment restored suppressed hepatic hepcidin expression and normalized elevated liver and serum iron that had resulted from uncontrolled diabetes.

Full detail, limits and 1 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective findings. Yellow

Limits on what this shows

  • Key negative/null: A human study reporting insulin therapy correcting hepcidin levels in type 2 diabetes (PMID 28584599) was located via search but could not be opened during this review (PubMed bot-verification block; Europe PMC rate-limited); it is not used to support this grade and is flagged in the sources list as unverified.
  • At-risk subgroups: None identified as an insulin-caused iron-deficiency risk; if anything, the uncontrolled-diabetes state itself, not insulin, is associated with iron overload in these models.

Regulatory status

Not addressed in the label.

Population evidence

Animal study (Tier B): "Hepcidin Is Directly Regulated by Insulin and Plays an Important Role in Iron Overload in Streptozotocin-Induced Diabetic Rats," Diabetes, 2014. Type 1- and type 2-model STZ diabetic rats; neutral insulin (Novo Nordisk) given subcutaneously. Liver hepcidin fell roughly 40% in diabetic rats and was reversed by insulin; hepatic and serum iron, elevated in diabetic rats, were significantly lowered toward normal by insulin treatment.

Mechanism

Named: insulin directly upregulates hepcidin transcription via STAT3 signaling, partly ERK-mediated, independent of SMAD4/BMP signaling.

Counter-evidence held on record

None found opposing the normalizing direction in the sources that could be verified. Reverse-direction/protective finding, graded as an entry fully independent from Copper. Do not use to suggest iron supplementation is needed because of insulin aspart use.

  • The role of insulin therapy in correcting hepcidin levels in patients with type 2 diabetes mellitus. Oman Med J, 2017. PMID 28584599. — Human study, insulin therapy and hepcidin in type 2 diabetes.Could not be opened during this review: PubMed page returned a bot-verification (reCAPTCHA) challenge; a follow-up Europe PMC query for the same record was rate-limited (HTTP 429). Not used to support any grade in this dossier.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk

Not graded — disclosed evidence gap

See study details

No drug-specific or class-level evidence was found that insulin, or insulin aspart specifically, alters gut microbiome composition.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Searched PubMed with multiple phrasings ("insulin therapy gut microbiome randomized," "insulin therapy gut microbiota type 1 diabetes randomized"), Europe PMC, and general web search before the web-search budget for this session was exhausted. Human studies describing microbiome alterations in long-standing type 1 diabetes were found, but these compare people with diabetes to healthy controls, not insulin-treated to insulin-naive patients, so they are confounded by the underlying disease (Hard Rule 6) and do not support attributing the change to insulin, even at Tier C. No circulating consumer claim linking insulin to microbiome disruption was found. Both conditions for ungraded are met: no Tier B/C evidence and no claim to rebut.

Tooling note

Europe PMC (www.ebi.ac.uk) returned repeated 403/429 responses partway through this review; a targeted re-check of that channel specifically for this category is warranted in a future revision.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

ATP production

Yellow — Low

See study details

Intravenous insulin infusion in humans increased mitochondrial ATP production and oxidative-phosphorylation-related gene transcription and enzyme activity in skeletal muscle; a positive/supportive finding, not a depletion, graded fully independent from the mitochondrial burden and oxygen-delivery entries.

Full detail, limits and 2 references

What the grade means here: low/theoretical: mechanistic plausibility only (Tier B), or class extrapolation (Tier C) where another class member has real data but this drug does not; also used for context flags and reverse-direction/protective findings. Yellow

Limits on what this shows

  • Key negative/null: The same study found a reduced (blunted, not absent) stimulation of muscle mitochondrial ATP production by insulin in type 2 diabetic patients compared with non-diabetic controls.
  • At-risk subgroups: None in the depletion sense; insulin-resistant patients may show an attenuated benefit rather than a harm.

Regulatory status

Not addressed in the label.

Population evidence

Human interventional study (Tier B/C): Stump CS, Short KR, Bigelow ML, Schimke JC, Nair KS. "Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts." Proc Natl Acad Sci USA. 2003;100:7996-8001. PMID 12808136. 8-hour insulin infusion compared type 2 diabetic patients with non-diabetic controls; insulin type used was not confirmed as insulin aspart specifically (treated as class-level).

Mechanism

Named: insulin enhances mitochondrial mRNA transcription (including cytochrome c oxidase subunits and NADH dehydrogenase), protein synthesis rates, and citrate synthase/cytochrome c oxidase enzyme activity, increasing ATP production rates.

Counter-evidence held on record

Blunted response documented in type 2 diabetes versus controls within the same study; this is an attenuation of benefit, not a reversal to harm. Positive/class-level finding, not run in insulin aspart specifically. Not a basis for any supplement recommendation, and not to be merged with the Mitochondrial burden or Oxygen delivery/utilization entries.

  • Stump CS, Short KR, Bigelow ML, Schimke JC, Nair KS. Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts. Proc Natl Acad Sci USA. 2003;100(13):7996-8001. PMID 12808136. — Human interventional insulin-infusion study, type 2 diabetic patients vs. non-diabetic controls. Insulin type used not confirmed as insulin aspart (class-level).Cohort: insulin infusion, formulation not confirmed as insulin aspart — treated as class-level evidence.
  • Boirie Y. Insulin regulation of mitochondrial proteins and oxidative phosphorylation in human muscle. Trends Endocrinol Metab. 2003. DOI 10.1016/j.tem.2003.09.002. — Commentary/mini-review on Stump et al. 2003.

Oxygen delivery/utilization

Not graded — disclosed evidence gap

See study details

No drug-specific or class-level evidence was found that insulin aspart affects hemoglobin, hematocrit, red-cell mass, or tissue oxygen delivery.

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. Ungraded

Limits on what this shows

  • Why no grade: Searched PubMed and Crossref for insulin/insulin aspart combined with hemoglobin, hematocrit, oxygen delivery, and endothelial nitric oxide/vasodilation. Found only literature on endogenous insulin resistance impairing endothelial nitric-oxide signaling (a disease-state finding about insulin resistance, not an effect of administering exogenous insulin aspart) and glycated-hemoglobin (HbA1c) data, which measures glycemic control rather than oxygen-carrying capacity and is excluded under the outcome-vs-nutrient distinction. No circulating claim was found. Both conditions for ungraded are met.

Tooling note

Part of the search for this category relied on Crossref bibliographic search rather than full-text PubMed/Europe PMC access, which was intermittently rate-limited during this review; disclosed for a future revision to re-check.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • DHEA

    Where it comes from: Consumer wellness website ("Common Medications That Rob the Body of Nutrients," Wellness Resources), a non-primary source with no citation for the claim.

    Why it fails: No Tier A, B, or C evidence was found supporting reduced DHEA with insulin therapy. The closest related human study found (PMID 35928897, short-term intensive insulin therapy in men with newly diagnosed type 2 diabetes) reported insulin therapy upregulating 3-beta and 17-beta hydroxysteroid dehydrogenase enzyme activity, which does not demonstrate DHEA depletion and, if anything, points toward increased steroidogenic enzyme activity, not a depletion narrative.

All references used above
  1. DailyMed, NovoLog (insulin aspart) injection, solution — full prescribing information. — U.S. FDA-approved regulatory label. National Library of Medicine.
  2. StatPearls: Insulin (regular and other types). — NCBI Bookshelf, general pharmacology reference, class-level (Tier B/C), not insulin aspart-specific.
  3. WHO Collaborating Centre for Drug Statistics Methodology, ATC/DDD Index, code A10AB05. — ATC classification and defined daily dose reference.
  4. Stump CS, Short KR, Bigelow ML, Schimke JC, Nair KS. Effect of insulin on human skeletal muscle mitochondrial ATP production, protein synthesis, and mRNA transcripts. Proc Natl Acad Sci USA. 2003;100(13):7996-8001. PMID 12808136. — Human interventional insulin-infusion study, type 2 diabetic patients vs. non-diabetic controls. Insulin type used not confirmed as insulin aspart (class-level).Cohort: insulin infusion, formulation not confirmed as insulin aspart — treated as class-level evidence.
  5. Boirie Y. Insulin regulation of mitochondrial proteins and oxidative phosphorylation in human muscle. Trends Endocrinol Metab. 2003. DOI 10.1016/j.tem.2003.09.002. — Commentary/mini-review on Stump et al. 2003.
  6. Dorothy Hodgkin Lecture 2024: Insulin regulation of mitochondrial biogenesis and function. — Review article, PMC12221207, background mechanism reference for mitochondrial burden and ATP production entries.
  7. Failla ML, Kiser RA. Hepatic and renal metabolism of copper and zinc in the diabetic rat. Am J Physiol Endocrinol Metab. 1983;244(2):E115. DOI 10.1152/ajpendo.1983.244.2.e115. PMID 6824071. — Animal study (STZ-diabetic rats), insulin treatment effect on copper status in liver, kidney, intestine.
  8. Failla ML, Gardell CY. Effect of insulin treatment on tissue zinc, copper, and manganese in the diabetic rat, 1985. PMID 3901016 (identified via PubMed search listing). — Animal study, BB Wistar diabetic rats; daily insulin injections normalized tissue trace-mineral changes.Full text not opened; details drawn from PubMed search-results listing view.
  9. Hepcidin is directly regulated by insulin and plays an important role in iron overload in streptozotocin-induced diabetic rats. Diabetes. 2014;63(5):1506-1518. — Animal study (STZ type 1- and type 2-model diabetic rats), neutral insulin (Novo Nordisk) subcutaneous; insulin normalized hepcidin suppression and iron overload.
  10. The role of insulin therapy in correcting hepcidin levels in patients with type 2 diabetes mellitus. Oman Med J, 2017. PMID 28584599. — Human study, insulin therapy and hepcidin in type 2 diabetes.Could not be opened during this review: PubMed page returned a bot-verification (reCAPTCHA) challenge; a follow-up Europe PMC query for the same record was rate-limited (HTTP 429). Not used to support any grade in this dossier.
  11. Chronic insulin treatment causes insulin resistance in 3T3-L1 adipocytes through oxidative stress. Free Radic Res. 2008;42(6). — In vitro adipocyte cell-model study, generic/unspecified insulin, chronic supraphysiologic exposure increased oxidative-stress markers.
  12. The effects of sodium dichloroacetate on mitochondrial dysfunction and neuronal death following hypoglycemia-induced injury, 2019. — Animal/cell study on hypoglycemia-induced mitochondrial dysfunction; pyruvate dehydrogenase kinase upregulation suppressing ATP formation.
  13. Recurrent hypoglycemia worsens brain mitochondrial dysfunction in diabetic rat models, 2019. — Animal study, insulin-treated diabetic rats; recurrent hypoglycemia enhanced mitochondrial dysfunction and brain injury.
  14. Imel EA, Econs MJ. Approach to the hypophosphatemic patient. PMC3319220. — Narrative review; describes the DKA/insulin cellular-phosphate-uptake mechanism without drug-level stratification (Tier C).
  15. Yoshida K et al. Impaired cardiac and neurological function with mild hypophosphatemia during insulin therapy for diabetic ketoacidosis: a case report. J Diabetes Investig. 2021. DOI 10.1111/jdi.13357. — Case report, insulin therapy for DKA and hypophosphatemia.Specific insulin formulation used in this case was not confirmed during this review; treated as class-level, not insulin aspart-specific.
  16. PubMed-indexed case report (2017), title concerning painful and prolonged muscle cramps and electrolyte changes with insulin injection. — Noted a null finding: magnesium unchanged after insulin injection while potassium dropped.Full bibliographic detail (authors, journal) could not be confirmed; a follow-up Crossref query to verify was blocked by proxy rate-limiting and not retried further in this session.
  17. Short-time intensive insulin therapy upregulates 3-beta- and 17-beta-hydroxysteroid dehydrogenase levels in men with newly diagnosed type 2 diabetes mellitus. PMID 35928897. — Human study, insulin therapy and steroidogenic enzyme activity; used to help rebut the DHEA depletion claim.
  18. The gut microbiome composition is altered in long-standing type 1 diabetes and associates with glycemic control and disease-related complications. Diabetes Care. 2022;45(9):2084. — Human disease-state (not drug-intervention) microbiome study; confounded by indication for insulin-attribution purposes.
  19. Wellness Resources. Common Medications That Rob the Body of Nutrients. — Consumer wellness website, Tier D, source of the DHEA circulating claim addressed in Fails Verification.
  20. U.S. Pharmacist. Drug-Induced Nutrient Depletions: What Pharmacists Need to Know. — Consumer/professional depletion-list reference; confirmed insulin is not mentioned as depleting any nutrient in this source.
  21. Coastal Pharmacy and Wellness. Drug-Induced Nutrient Depletions: the Warnings Not Listed on Your Rx Label. — Consumer depletion-list reference; confirmed injectable insulin is not discussed (only metformin, under biguanides).
  22. Alive Magazine. Common Drugs Deplete Nutrients. — Consumer depletion-list reference; confirmed injectable insulin is not discussed (only oral diabetes drugs).